Location: Copenhagen, Denmark
Date: October 7 to October 11
European Society for Medical Oncology Conference.
Vision of the ESMO
13890_PR < 5000 patients denied access to new, life-saving drugs every year in Europe
ESMO 2016: Scientific Programme Highlights
Full-dose neoadjuvant chemotherapy: Interi
First-line ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC)
Primary analyss from OAK, a randomized phase III study comparing atezolizumab with docetaxel in patients with advanced NSCLC.
AFFINITY phase 3 trial. Chemotherapy of Prostate Cancer
Phase III trial of sunitinib (SU) vs placebo (PBO) as adjuvant treatment for high-risk renal cell carcinoma (RCC) after nephrectomy (S-TRAC)
Results from ALLIANCE A031203 trial
Eribulin in Soft Tissue Sarcomas (Leiomyosarcoma)
ESMO 2016: Congress Highlights
MONALEESA-2 study and Novelties in breast cancer therapy
Full-dose neoadjuvant chemotherapy
New results in immun check point inhibition Lung Cancer
The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients: An international multicentre hospital-based retrospective cohort study
Highlights of Late Breaking Trials
Checkpoint inhibitors for the treatment of orphan malignancies
New therapeutical option: A mechanism of action study. An oncolytic adenovirus in patients with colon, lung, bladder and renal carcinoma.